Skip to main content

Selective Inhibition of NOTCH by novel γ-Secretase Inhibitors in Tumours

Project description

Two novel Notch pathway inhibitors as an antitumour therapeutics

The self-renewal of multipotent cancer stem cells (CSC) strongly correlates with tumour resistance associated with tumour heterogeneity. The evolutionarily conserved Notch signalling pathway is involved in cell-cell communication and controls multiple cell differentiation processes during embryonic and adult life. The Notch CSC signalling pathway is frequently deregulated in human cancers. The EU-funded INGSIGHT project will assess the technical and commercial feasibility of two novel inhibitors of the Notch pathway with the potential to radically improve cancer therapy outcomes. The study will demonstrate the maximum tolerated dose in normal tissues, the therapeutic effects using tumour models, and will conduct market analysis to ensure the selection of the optimal business strategy.

Call for proposal

ERC-2020-PoC
See other projects for this call

Host institution

UNIVERSITEIT MAASTRICHT
Address
Minderbroedersberg 4
6200 MD Maastricht
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 150 000

Beneficiaries (1)

UNIVERSITEIT MAASTRICHT
Netherlands
EU contribution
€ 150 000
Address
Minderbroedersberg 4
6200 MD Maastricht
Activity type
Higher or Secondary Education Establishments